Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 20 analyst ratings
Hold
Strong Buy 10%
Buy 15%
Hold 65%
Sell 5%
Strong Sell 5%

Bulls say

Humana's financial outlook appears positive, driven by a 500 basis point improvement in Group MA margins through effective re-contracting strategies, which suggests enhanced profitability. The company is expecting robust revenue growth across multiple segments, including Specialty and Home delivery, where management anticipates that marketing cost moderation and improved risk adjustments will further boost margins over time. Additionally, the strong performance in the CenterWell segment, with a 16% revenue increase primarily from pharmacy services, highlights the firm's ability to generate significant earnings despite operational challenges, positioning Humana favorably within the competitive healthcare landscape.

Bears say

The negative outlook on Humana's stock is primarily influenced by anticipated headwinds in Medicare Advantage (MA) utilization and an increase in competition within the sector, which may adversely affect membership growth and reimbursement rates. Additionally, a decline in MA Star ratings is projected to result in a significant EPS drag of approximately $22 for 2026, further undermining the firm’s earnings outlook. Finally, decreased net investment income due to lower interest rates, combined with operational cost management challenges, may lead to sustained pressure on overall financial performance.

Humana (HUM) has been analyzed by 20 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 15% recommend Buy, 65% suggest Holding, 5% advise Selling, and 5% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 20 analysts, Humana (HUM) has a Hold consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $241.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $241.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.